$YDES News
Last published 15h ago
- 15h agoYDESYD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye DiseaseGlobeNewswireFDA agrees to provide written guidance by January 4, 2027, to support development of YDB-LMSCEV-001
- 3w agoYDESYD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness ProgramsGlobeNewswireTAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection
- 2mo agoYDESYD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026GlobeNewswireTAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and
- 2mo agoYDESYD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health InstituteGlobeNewswireTAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and
- 3mo agoYDESYD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health InstituteGlobeNewswireTwo chrono-nutrition formulations — a daytime lipid-soluble "Golden Triangle" formula and a nighttime zinc-plus-calcium formula — were developed in collaboration with the Taiwan CDHA and FHI. The Company intends
- 3mo agoYDESYD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus ResearchGlobeNewswirePublished in Bioengineering, a collaborative study with Taipei Medical University researchers identifies key molecular candidates to help guide the development of regenerative therapies for corneal disease. TAIPEI,
- 3mo agoYDESYD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in CanadaGlobeNewswireThe six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada Taipei, Taiwan, July 28, 2026 (GLOBE NEWSWIRE)
- 3mo agoYDESYD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical ServicesGlobeNewswireTaipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and
- 4mo agoYDESYD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection OperationsGlobeNewswireTaipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and
- 6mo agoYDESYD Bio Limited Reports Full Year 2025 Financial ResultsGlobeNewswireTAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 7mo agoYDESYD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United StatesGlobeNewswireTaipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 8mo agoYDESYD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory PlatformGlobeNewswireTaipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 9mo agoYDESYD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell TherapyGlobeNewswireTAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 10mo agoYDESYD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug DevelopmentGlobeNewswireTaipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 10mo agoYDESYD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial RoadmapGlobeNewswireTaipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 11mo agoYDESYD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations CenterGlobeNewswireTaipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 11mo agoYDESYD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWANGlobeNewswireTaipei, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 11mo agoYDESYD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early DetectionGlobeNewswireTaipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 11mo agoYDESYD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome TherapeuticsGlobeNewswireTaipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 1y agoYDESYD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer MonitoringGlobeNewswireTaipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQGM:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 1y agoYDESYD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDESGlobeNewswireTaipei, Taiwan, Oct. 20, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQGM:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 1y agoYDESYD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing CapabilitiesGlobeNewswireTaipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 1y agoYDESYD Bio Limited Reports Unaudited Half Year 2025 Financial ResultsGlobeNewswireTAIWAN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic
- 1y agoYDESYD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global MarketPR NewswireYD Bio Limited ("YD Bio Ltd" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology...
- 1y agoYDESYD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global MarketGlobeNewswireStrategic Move Positions YD Bio Limited for Accelerated Innovation and Market ExpansionTrading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market